Some embodiments of the invention relate to a system for delivering to a subject at least one pre-determined amount of THC, the system comprising: a memory which stores a scheduled regimen for delivery of THC to the subject, the scheduled regimen defining: a maximal amount of THC to be delivered, the amount being 0.75 mg THC or less, and a time period within which that amount is delivered, the time period being 2 hours or longer; a decision module which decides, according to the scheduled regimen, if a delivery should take place; and an inhaler device for delivering THC to the subject, the inhaler device comprising a controller which carries out delivery of THC based on the decision made by the decision module.

Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.

Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.

The present invention provides a modulator of Kv3.1 and/or Kv3.2 and/or Kv3.3 channels for use in the prophylaxis or treatment of pain. Modulators for use in the prophylaxis or treatment of pain include compounds of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof and/or derivative thereof: ##STR00001##

The present invention provides a modulator of Kv3.1 and/or Kv3.2 and/or Kv3.3 channels for use in the prophylaxis or treatment of pain. Modulators for use in the prophylaxis or treatment of pain include compounds of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof and/or derivative thereof: ##STR00001##

This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF antagonist. The NGF antagonist and the TNF antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF antagonist administered alone.

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

The present invention concerns a pharmaceutical formulation for administering paracetamol by buccal/gingival route consisting of a hydroalcoholic solution comprising dissolved paracetamol, characterised in that: # the mass of paracetamol is between 95 mg and 190 mg, # the volume of said hydroalcoholic solution is between 1.0 ml and 2.0 ml, # the degree of alcohol of said hydroalcoholic solution is between 48.5 and 52.5, and # the concentration of paracetamol in said hydroalcoholic solution is between 85 mg/ml and 110 mg/ml. The present invention also concerns said pharmaceutical formulation for the use of same for accelerating the speed at which paracetamol passes through the blood-brain barrier, and the use thereof as a drug, in particular for the symptomatic treatment of pain or fever.

The present invention relates to the use, as an agent for salting out an active substance in a composition for a dressing, of a copolymer of a salt of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulphonic acid and the 2-hydroxyethyl ester of propenoic acid. It also relates to dressings of the type comprising at least one fatty substance and/or an elastomeric matrix and at least one active substance, which incorporate the aforementioned copolymer.

Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.